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puBackground: Comprehensive studies on costs of moderate to severe plaque psoriasis (MSPP) have not
been conducted in the United States.Objective: We sought to evaluate current health care resource use, productivity, and costs among patients
with MSPP in routine practice.Methods: A total of 200 adults seeking MSPP treatment enrolled in 9 US sites. Consented patients reported
symptoms, treatment, lost productivity, and costs; 6-month retrospective chart review captured health care
resource use and clinical characteristics. Costs were assigned to health care resource use and lost
productivity using standard algorithms. Differences by Psoriasis Area and Severity Index (PASI) group,
based on PASI score (#10,[10-#20,[20) at enrollment, were evaluated. Analyses included descriptive
statistics and analysis of variance or Kruskal-Wallis tests.Results: Most patients (79.5%) were prescribed 1 or more MSPP medications (mean: 1.5); 36.0% and 9.0%
received self-administered biologics and systemic therapies, respectively. Mean number of nonprescription
treatments was 12.3. Differences by PASI group were observed for overall work and activity impairment
(P \ .02). Six-month total MSPP direct costs per patient were $11,291; indirect costs were $2101 and
differed across PASI groups (P = .0008).Limitations: This study enrolled patients with MSPP actively seeking care.Conclusion: Despite treatment, a number of patients with MSPP continue to experience moderate to
severe PASI scores, impaired functioning, and high costs suggesting a need for new treatment options.
( J Am Acad Dermatol 2015;73:585-93.)
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psoriasis are thought to have moderate to
severe plaque psoriasis (MSPP).1-3 Plaque
psoriasis has been associated with depression,Covance Market Access Services Inc, Gaithersburga and San
iegob; Pfizer Inc, Grotonc; Dermatology Center of Indianad;
niversity of Louisvillee; and Johnson Dermatology, Fort Smith.f
research was supported by Pfizer.
osure: Dr Cheng and Ms Schaefer are employees of Covance
arket Access Services Inc, which was paid by Pfizer to design
d execute this study and to develop this manuscript. Dr Cole
as an employee of Covance Market Access Services Inc at the
e of the study; currently, Dr Cole is an employee of
armaceutical Product Development LLC. Dr Cappelleri and
r Mamolo are employees of Pfizer. Dr Fowler, Dr Guenthner,
d Dr Johnson were paid investigators for the study; they
ere not financially compensated for collaborative efforts on
blication-related activities.immune-mediated inflammatory conditions, lym-
phoma, metabolic syndrome and obesity, and
myocardial infarction2,4; severe psoriasis has even
been associated with shortened survival.1,2 MSPP hasAccepted for publication June 24, 2015.
Reprints not available from the authors.
Correspondence to: Caroline P. Schaefer, MBA, Covance Market
Access Services Inc, Gaithersburg MD. E-mail: caroline.
schaefer@covance.com.
Published online August 4, 2015.
0190-9622
 2015 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
http://dx.doi.org/10.1016/j.jaad.2015.06.049
585
J AM ACAD DERMATOL
OCTOBER 2015
586 Schaefer et albeen shown to negatively impact health-related
quality of life5; patients with psoriasis report similar
or worse health-related quality of life compared with
chronic diseases such as diabetes.6
Guidelines discuss patients with MSPP receiving
conventional systemic therapies, biologic agents,
phototherapy, and topical agents alone or in combi-CAPSULE SUMMARY
d The economic burden of moderate to
severe plaque psoriasis has been studied
in Europe and Canada.
d This study captures medication use,
health care resource use, lost
productivity, direct and indirect costs
associated with moderate to severe
plaque psoriasis in the United States by
Psoriasis Area and Severity Index score.
d Results can help US clinicians understand
impacts of real-world treatment patterns
and remaining unmet need.nation.2,7,8 Previous studies,
such as the National Psoriasis
Foundation survey (2003-
2005), have found a substan-
tial proportion of patients
do not seek treatment or are
undertreated.9
MSPP costs include direct
costs to payers, (eg, der-
matologist office visits,
prescription or physician-
administered treatments, hos-
pitalization), out-of-pocket
costs to patients, and indirect
costs (eg, lost productivity as
a result of absenteeism).9-15
Most economic studies to
date have included all pa-*PASI and BSA were calculated at the site. Sites received study-
specific training on calculating the scores for PASI and BSA.tients with psoriasis.15 An analysis of 2003 data
reported significantly greater annual costs for MSPP
compared with mild psoriasis ($10,593 vs $5011) and
identified the primary cost driver of MSPP to be
outpatient visits.10 More recent observational studies
have identified pharmacotherapy and other treat-
ments as primary cost drivers.14,16,17 One study
reported the average annual cost of MSPP to be
$11,029 and $26,708 for patients treated with con-
ventional systemics and biologics, respectively.17 Use
of alternative, nonmedical therapies and correspond-
ing high out-of-pocket costs among patients with
MSPP have also been observed.12,18
Psoriasis has been associated with negative im-
pacts on productivity and finances.6,11-16,19-23 In 1
United Kingdom study, patients missed an average of
26work days annually as a result of MSPP.19 An Italian
study reported that absenteeism (or loss of leisure
time for nonemployed patients) accounted for 32% of
total MSPP-related costs.11 A recent US survey found
that compared with patients with mild psoriasis,
patients with severe disease were less likely to work
full-time and significantly more likely to report that
psoriasis was the reason for not working.20
Although studies have been conducted in
Europe11-13,16,24-27 and Canada14,28-30 to assess
health care resource use (HCRU), productivity, and
costs associated with psoriasis, at the time of this
study no comprehensive studies of the economic
burden of MSPP, including direct and indirect costs,had been conducted in the United States to our
knowledge. Because extrapolating non-US findings
to the United States is not straightforward as a result
of differences in health care delivery systems and
costs across countries, a gap remains in the under-
standing of MSPP costs in the United States. Recently
the United States Centers for Disease Control andPrevention (CDC) published
recommendations for addi-
tional public health research
into the HCRU, impact on
ability to work, and costs
associated with psoriasis.31,32
This study aimed to evaluate
the economic burden of
MSPP in the United States
by capturing its impact
on HCRU, productivity, and
direct and indirect costs
among patients actively
seeking treatment via patient
survey and medical chart
review.METHODS
Study design and data sources
This US observational study included a cross-
sectional survey and 6-month retrospective chart re-
view. Patients with plaque psoriasis and body surface
area (BSA) of 10 or higher at enrollment or in the prior
6 months, or on systemic therapy or phototherapy (or
both) for MSPP at screening were eligible.* Eligible
patients were 18 years or older, willing and able to
provide written informed consent, able to read and
understand English, treated at the physician’s practice
for at least 6 months, and given a diagnosis of MSPP
more than 6 months before enrollment. Patients were
ineligible if they had participated in an investigational
drug study in the 6 months before enrollment; had a
serious or unstable medical or psychological condition
that, in the opinion of the physician, would compro-
mise participation in the study; or had psoriasis other
than plaque psoriasis.
Patients with MSPP were recruited (January
through May 2012) during a routine physician office
visit at 1 of 9 participating sites: 8 community-based
dermatologists and 1 primary care physician. The 9
sites were located in 8 US states: Nebraska, Illinois,
North Carolina, Indiana, Arkansas, California,
Kentucky, and Florida. There was competitive
enrollment among sites until the overall target
Abbreviations used:
BSA: body surface area
CDC: Centers for Disease Control and
Prevention
HCRU: health care resource use
MSPP: moderate to severe plaque psoriasis
PASI: Psoriasis Area and Severity Index
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site was allowed to enroll more than 40 patients.
Patients completed a cross-sectional survey that
included questions about sociodemographics, psori-
asis clinical characteristics and symptoms, current
employment status, changes in employment status
as a result of MSPP, out-of-pocket costs related to
psoriasis over the past 4 weeks, and several validated
patient-reported outcome instruments, including
the Work Productivity and Activity Impairment:
Psoriasis, a 6-item instrument assessing overall work
impairment, ie, absenteeism, presenteeism, and ac-
tivity impairment33 attributable to MSPP. Study site
personnel completed a case report form based on a 6-
month retrospective chart review that captured
Psoriasis Area and Severity Index (PASI) score;
percent BSA; clinical history and characteristics; and
MSPP-relatedHCRUover the past 6months, including
hospitalizations, office-based and hospital outpatient
visits and treatments (eg, phototherapy), tests, pro-
cedures, and infusions performed, use of
a phototherapy home device, and prescribed
medications.
Patients provided written informed consent,34
and study materials were approved by Schulman
Associates Institutional Review Board Inc
(Cincinnati, OH).Calculation of MSPP costs
Costing algorithms were used to assign 2012 unit
costs (US$) from published sources to HCRU data
captured in the retrospective chart review and
patient-reported lost productivity data35 to calculate
6-month costs. Sources for unit costs and details of
the costing approach are presented in the ‘‘Costs of
MSPP’’ section of this article.Analysis methods
Summary statistics were used to describe the
sample.36,37 Although all enrolled patients had mod-
erate to severe disease, PASI score at enrollment was
used to determine analysis groups, based on
European Medicines Agency psoriasis guidance:
less than or equal to 10 (mild), greater than 10 to
20 (moderate), and greater than 20 (severe).7For continuous variables, differences by PASI
group were compared using 1-way analysis of
variance or the Kruskal-Wallis test if normality of
the data distribution was not confirmed. In cases
where Kruskal-Wallis was used, whereas the means
and SDs are presented, the P value presented is
based on the ranks and hence involves a difference
in population medians between independent
groups. The 95% confidence interval of the differ-
ence between group means also was reported by
PASI group. For categorical variables, differences by
PASI group were compared using the x2 or Fisher
exact test.
Statistical significance was evaluated at the 2-
tailed .05 level of significance. Statistical analyses
were performed using software (SAS, Version 9.1.3,
SAS Institute Inc, Cary, NC).
RESULTS
Demographic and clinical characteristics
Male and female patients were equally repre-
sented (N = 200) (Table I, available at http://www.
jaad.org). The mean age was 51.4 years; 62% were
employed. Mean PASI score at enrollment was 8.6;
71.5% were in the mild PASI group, 18.0% in the
moderate PASI group, and 10.5% had severe PASI.
Most patients (88.0%) were Caucasian. Statistically
significant differences across PASI groups were
observed for race and weight (P = .0097 and
P\ .0001, respectively).
Mean time since diagnosis was 15.6 years (me-
dian: 11.4 years). Mean BSA at enrollment was
10.8% overall; patients with moderate and severe
PASI had higher mean BSA scores (24.1% and
25.6%, respectively) than those with mild PASI
(5.2%, P\ .0001) (Table I). Based on retrospective
chart review, those with moderate PASI had wors-
ening BSA scores over the previous 6 months, with
the lowest mean scores at enrollment, whereas the
severe PASI group’s BSA had remained relatively
stable and high in the same time frame. Of patients,
72% reported psoriasis affected 3 or more body
parts (Fig 1). Comorbidities were prevalent (mean:
2.0) (Table I). In all, 59 (29.5%) subjects had
psoriatic arthritis in addition to their MSPP.
Treatment patterns and HCRU
Most patients (79.5%) were prescribed 1 or more
MSPPmedications (Table II, available at http://www.
jaad.org); 20.5% were not receiving any MSPP pre-
scription medication. Mean number of prescription
medications per patient was 1.5, with a significant
difference across PASI groups (P = .0162). Fig 2
presents the proportions of patients who received
biologics, systemics, phototherapy (at home or in
Fig 2. Moderate to severe plaque psoriasis medication use in the past 6 months. *Composed of
physician- and self-administered biologics including alefacept, infliximab, ustekinumab,
etanercept, and adalimumab. yComposed of physician- and self-administered conventional
systemic therapies including triamcinolone acetonide, cyclosporine, doxepin hydrochloride,
folic acid, hydrochlorothiazide and triamterene, hydroxyzine hydrochloride, methotrexate,
penicillin potassium, prednisone, and acitretin. Using the Fisher exact test, a significant
difference was observed across Psoriasis Area and Severity Index (PASI ) groups for topicals
(P = .0201) and biologics (P = .0130). For categorical variables, differences by PASI group were
compared using Fisher exact test if expected counts were less than 5 patients per cell.
Fig 1. Body parts affected by moderate to severe plaque psoriasis, as reported by patients.
Data for 4 patients were missing.
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use of topicals and biologics among the 3 PASI
groups were significant (P = .0201 and P = .0130,
respectively); the severe PASI group had the highest
proportion of patients reporting use of topicals. A
higher percentage (33.3%) of patients in the severe
PASI group were prescribed topicals only compared
with 15.4% and 19.4% in the mild and moderate PASI
groups, respectively. Approximately one third of
patients used 5 or more nonprescription psoriasis
treatments in the 4 weeks before enrollment.There was a mean of 3.4 MSPP office visits, 1.4
office-based tests and procedures, and 0.7 office-
based phototherapy sessions per patient in the past
6 months. Across the PASI groups, similar levels of
HCRU were observed.
Productivity and changes in employment
status
Among those employed, overall work impairment
as a result of MSPP was approximately 14% (Fig 3).
This was predominantly related to impairment at
Fig 3. Moderate to severe plaque psoriasis (MSPP). Mean Work Productivity and Activity
Impairment: Psoriasis (WPAI:PsO) scores. Raw scores are multiplied by 100 and expressed as
impairment percentages, with higher values indicating greater impairment.42 *Among those
employed for pay. WPAI:PsO scores are expressed as impairment percentages: absenteeism is
percent work time missed as a result of MSPP; presenteeism is percent impairment while
working as a result of MSPP; overall work impairment is percent overall impairment as a result
of MSPP, composed of absenteeism and presenteeism; and activity impairment is percent
activity impairment. Using the Kruskal-Wallis test, a significant difference in medians was
observed across Psoriasis Area and Severity Index (PASI ) groups for absenteeism (PASI $10:
0.0, 10\PASI #20: 0.0, PASI[20: 0.0; P = .0460), presenteeism (PASI $10: 0.0, 10\PASI #20:
10.0, PASI[20: 10.0; P = .0262), overall work impairment (PASI $10: 0.0, 10\PASI #20: 10.0,
PASI[20: 12.6; P = .0103), and activity impairment (PASI $10: 0.0, 10\PASI #20: 20.0,
PASI[20: 20.0; P\.0001). For continuous variables, differences by PASI group were compared
using Kruskal-Wallis if data were not normally distributed. Normality was assessed using
skewness and Kurtosis z-scores, wherein a z-score of \5.0 was considered as providing
sufficient evidence for normality to use the parametric test.43 Researchers have found analysis
of variance, which tests for differences in means, to be robust upward of a skewness z of 10 or
1244; however, we opted for a more conservative value of 5.0.
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(absenteeism). Overall work impairment was high-
est for the severe PASI group (25.0%). Mean activity
impairment was similarly high among moderate and
severe PASI groups (27.2% and 27.1%, respectively).
Differences across PASI groups were significant for
both Work Productivity and Activity Impairment:
Psoriasis scores (P = .0103 and P\ .0001) (Fig 3).
MSPP had no impact on employment status for
the majority of patients (n = 184) (Table III, available
at http://www.jaad.org). Significant differences
were observed across PASI groups for change in
roles as a result of MSPP (P\ .03).
In addition, there were significant differences
across PASI groups for the mean time spent applying
topicals (P = .0003) and vacuuming (P = .0145).Costs of MSPP
Average 6-month total direct costs per patient are
presented in Fig 4; the largest components were for
prescription treatments and office-based infusions
across the PASI groups. (All patients in the sample
had MSPP; the sample was then categorized by
baseline PASI score into three group: mild PASI,
moderate PASI, and severe PASI.) No significant
differences across PASI groups were observed for
total direct costs. Average 6-month total indirect
costs per patient increased from mild to moderate
to severe PASI groups (P = .0008) (Fig 5). Across the
3 PASI groups, average 6-month indirect costs
associated with lost work productivity accounted
for more than 75% of the total indirect cost per
patient.
Fig 4. Moderate to severe plaque psoriasis (MSPP). Mean 6-month direct costs (2012 US$).
*Includes out-of-pocket costs to patients for direct medical and nonmedical expenses. Patient-
reported out-of-pocket costs did not need to be monetized; 4-week costs were extrapolated to
26 weeks (multiplied by 6.5). The average 6-month out-of-pocket costs to patients for direct
medical expenses were higher than those for nonmedical expenses for all Psoriasis Area and
Severity Index (PASI ) groups; a significant difference across PASI groups was observed for the
nonmedical expenses: $309 for the moderate PASI group compared with $69 and $68 for the
mild and severe PASI groups, respectively (P = .0007). yIncludes direct costs to payers for
MSPP-related office-based visits, office-based tests and procedures (excluding infusions),
hospitalizations, and prescribed phototherapy home devices. Unit costs were assigned using
the fiscal year 2012 Medicare physician fee schedule, Hospital Outpatient Prospective Payment
System, and Hospital Inpatient Prospective Payment System; for each hospitalization reported,
the discharge diagnosis, procedures performed, and length of stay were used to identify
appropriate diagnosis-related groups to estimate costs. zUnit costs for MSPP-related office-
based infusions were assigned using the average sales price and fiscal year 2012 Medicare
physician fee schedule. xUnit costs for MSPP-related prescription treatments were assigned
using 2012 average wholesale price, adjusted for discounts and dispensing fees. Using the
Kruskal-Wallis test, no significant differences in medians were observed across PASI groups for
total 6-month direct costs per patient (means: $11,662 vs $10,460 vs $10,187; medians: $12,104
vs $4851 vs $5082; P = .4084). For continuous variables, differences by PASI group were
compared using Kruskal-Wallis if data were not normally distributed. Normality was assessed
using skewness and Kurtosis z-scores, wherein a z-score of\5.0 was considered as providing
sufficient evidence for normality to use the parametric test.43 Researchers have found analysis
of variance, which tests for differences in means, to be robust upward of a skewness z of 10 or
1244; however, we opted for a more conservative value of 5.0.
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This study describes current treatment patterns,
HCRU, lost productivity, and associated 6-month
direct and indirect costs among patients with MSPP
in US routine clinical practice. A strength of the study
is that it combines patient survey and chart review to
comprehensively capture economic burden,
including patient-reported nonprescription treat-
ments, out-of-pocket costs, work impairment, and
changes in employment status, which are not
captured using medical claims data.
Our samplewas similar to others based on a broad
set of clinical and demographic variables,6,23 and
there were few significant differences across PASI
groups. We observed that patients with severe PASI
tended to weigh more, and note that the associationbetween MSPP and weight or other comorbidities
associated with increased weight is an area for future
research suggested by the CDC.31,32
In our study, 49% of patients reported that 5 or
more body parts were affected by psoriasis, consis-
tent with European findings.23 Mean BSA scores at
enrollment and over the past 6 months in the
moderate and severe PASI groups suggest patients
with moderate PASI were worsening as a result of
fluctuation in disease, changes in treatment, or both.
To better understand those with PASI scores greater
than 10 to 20, additional research is warranted.
A majority of patients had mild PASI scores at
enrollment, suggesting patients were relatively well
treated, although they met the MSPP criteria. Many
patients were taking a biologic, and few patients
Fig 5. Moderate to severe plaque psoriasis (MSPP). Mean 6-month indirect costs (2012 US$).
*Based on patient-reported lost productivity because of changes in employment status as a
result of MSPP, including unemployment, early retirement, disability, or reduced work
schedule. Costs of employment status changes were calculated by multiplying mean hourly
wage in the United States45 and mean monthly disability payment46 by lost productive time
since change in employment status as a result of MSPP (up to 26 weeks). Using the Kruskal-
Wallis test, a significant difference in medians was observed across Psoriasis Area and Severity
Index (PASI ) groups for 6-month total indirect costs per patient (means: $1617 vs $2625 vs
$4503; medians: $0 vs $0 vs $2288; P = .0008). For continuous variables, differences by PASI
group were compared using Kruskal-Wallis if data were not normally distributed. Normality
was assessed using skewness and Kurtosis z-scores, wherein a z-score of\5.0 was considered
as providing sufficient evidence for normality to use the parametric test.43 Researchers have
found analysis of variance, which tests for differences in means, to be robust upward of a
skewness z of 10 or 1244; however, the authors opted for a more conservative value of 5.0.
yBased on patient-reported lost productivity as a result of absenteeism and presenteeism
measured by the Work Productivity and Activity Impairment: Psoriasis. Work-related
impairment costs were calculated by multiplying lost productive time by the mean hourly
wage in the United States45 according to method proposed by Lofland et al35; 1eweek costs
were extrapolated to 26 weeks.
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using phototherapy at home to manage their MSPP.
The most commonly reported treatment type across
all 3 PASI groups was topical therapy; although a
minority of patients in each group was treated with
topicals alone, the highest proportion was in the
severe PASI group. Although 20.5% of our sample
was not receiving any prescription medications for
their MSPP, this proportion was lower than previous
estimates of 37% to 39%.9 Earlier studies were
conducted around the time of Food and Drug
Administration approval of biologics for MSPP;
thus, differences in treatment patterns may be a
result of the availability of newer therapies. In
addition, patients in this study were actively seeking
care and thus, may have beenmore likely to receive a
prescription for their MSPP and also may have been
more motivated and/or diligent about managing
their disease than patients not included.
Overall work impairment as a result of MSPP
among those employed was consistent with another
US survey (15.5%),38 and largely driven by presen-
teeism. Although presenteeism was high for both the
moderate and severe PASI groups, those with severePASI reported higher levels of absenteeism and
changes in employment status as a result of MSPP,
which explains their higher total indirect costs
compared with the other PASI groups.
MSPP is a common condition that imparts pro-
found economic impact on payers, employers, and
patients. There are limited published US studies that
assess the economic burden of MSPP10,17,20,39,40 and
none to our knowledge that provide a comprehen-
sive assessment of the economic burden.31,32
Patients with MSPP in our study had high direct costs
across PASI groups, driven by prescription treat-
ments and office-based infusions. Total direct costs
were comparable with previous estimates among
patients with MSPP treated with biologics15,17,40 and
exceeded published annual direct costs of rheuma-
toid arthritis.41 Use of high-cost treatments among
mild and moderate PASI groups was prevalent,
suggesting consistent treatment patterns among
patients with MSPP, with a proportion who are well
controlled. Compared with previous French results,
out-of-pocket medical care costs to patients were
higher and the proportion as a result of nonprescrip-
tion treatments was lower in our sample.12 Indirect
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PASI severity worsened. Total costs, cost drivers, and
proportion of costs driven by indirect costs observed
in this US study were comparable with several recent
non-US studies11,14,16; although, differences in health
care systems limits the degree to which such com-
parisons can be made. The results suggest that costs
and expenses related to HCRU and lost productivity
incurred by the proportion of patients whoseMSPP is
not well controlled are markedly higher than those
patients who experience better treatment outcomes.
Limitations
Several potential limitations should be considered
when interpreting study findings. The study focused
on patients with MSPP actively seeking care. Thus,
our sample may not be representative of patients
with MSPP in the general population who are
untreated or not regularly seeking care.
Retrospective review ofmedical recordsmay have
led to underreporting of HCRU, as enrolling sites
may not have recorded care provided elsewhere for
their patients’ psoriasis. Although sites were in-
structed to discuss MSPP-related care provided
outside the study site with patients, it is possible
some MSPP HCRU was not captured. Direct costs
were assigned using a standard algorithm; actual
costs to the payer may be higher or lower. The
Medicare fee schedule tends to underestimate costs,
as private insurers may reimburse at higher rates.
Out-of-pocket costs and lost productivity data were
based on patient recall and extrapolated to 6months;
this may have resulted in overestimation or under-
estimation of costs.
Conclusions
To our knowledge, this is one of the first studies to
comprehensively evaluate the economic burden of
MSPP in the United States, including direct costs to
payers, out-of-pocket costs to subjects, and indirect
costs as a result of lost productivity. Despite sub-
stantial HCRU, a proportion of patients continue to
experience work and activity impairment, moderate
to severe PASI scores, and high costs. For patients
whose MSPP is not well controlled, different treat-
ment options should be explored until better out-
comes and patient satisfaction are achieved.
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Table I. Demographic and clinical characteristics of the participating patients
Characteristic
Overall
(n = 200)
PASI #10
(n = 143, 71.5%)
10\PASI #20
(n = 36, 18.0%)
PASI[20
(n = 21, 10.5%) P value
Age, mean (SD), y* 51.4 (14.08) 52.0 (14.45) 53.1 (12.62) 44.8 (12.50) .0653
Male, n (%)y 100 (50.0) 66 (46.2) 24 (66.7) 10 (47.6) .0859
Race, n (%)y .0087
Caucasian 176 (88.0) 131 (91.6) 26 (72.2) 19 (90.5)
Other 24 (12.0) 12 (8.4) 10 (27.8) 2 (9.5)
Height, mean (SD), in* 67.2 (3.72) 66.9 (3.66) 67.9 (3.68) 68.6 (3.81) .0601
Weight, lb
Mean (SD)z 201.0 (53.11) 190.4 (43.88) 214.5 (56.66) 250.0 (71.58) \.0001
Median 193.0 185.0 202.0 254.0
Employment status, n (%)y .2996
Missing 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0)
Employed for pay 123 (61.5) 87 (60.8) 20 (55.6) 16 (76.2)
Not employed for pay 76 (38.0) 55 (38.5) 16 (44.4) 5 (23.8)
Missing 3 (3.9) 1 (1.8) 1 (6.3) 1 (20.0)
Disabled 16 (21.1) 12 (21.8) 3 (18.8) 1 (20.0)
Retired 32 (42.1) 24 (43.6) 6 (37.5) 2 (40.0)
Unemployed 12 (15.8) 8 (14.5) 4 (25.0) 0 (0.0)
Full-time homemaker 8 (10.5) 7 (12.7) 1 (6.3) 0 (0.0)
Other 5 (6.6) 3 (5.5) 1 (6.3) 1 (20.0)
Health insurance coverage, n (%) N/A
Missing 14 (7.0) 8 (5.6) 3 (8.3) 3 (14.3)
No 26 (13.0) 13 (9.1) 9 (25.0) 4 (19.0)
Yes 160 (80.0) 122 (85.3) 24 (66.6) 14 (66.6)
Prescription coverage, n (%) 159 (79.5) 120 (83.9) 25 (69.4) 14 (66.7) .0254
Comorbidity reported, n (%)x 150 (75.0) 107 (74.8) 26 (72.2) 17 (81.0) N/A
Comorbidities, mean (SD)*{ 2.0 (1.14) 2.0 (1.10) 2.3 (1.34) 2.1 (1.05) .4729
BSA on date of assessment
Mean (SD)zk 10.8 (13.98) 5.2 (6.17) 24.1 (17.67) 25.6 (18.85) \.0001
Median 6.0 3.0 20.0 20.0
PASI on date of assessment
Mean (SD)zk 8.6 (11.12) 3.3 (2.52) 13.9 (2.29) 36.0 (11.60) N/A
Median 4.3 2.80 13.65 34.00
Time since diagnosis, y
Mean (SD)z 15.6 (14.57) 15.8 (14.60) 17.8 (15.08) 10.4 (12.74) .0828
Median 11.4 11.2 18.2 3.25
Patient-reported psoriasis severity, n (%)y \.0001
Missing 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0)
Severe 31 (15.5) 9 (6.3) 14 (38.9) 8 (38.1)
Moderate 56 (28.0) 30 (21.0) 14 (38.9) 12 (57.1)
Mild 41 (20.5) 35 (24.5) 6 (16.7) 0 (0.0)
Almost clear 60 (30.0) 57 (39.9) 2 (5.6) 1 (4.8)
Clear (no psoriasis) 11 (5.5) 11 (7.7) 0 (0.0) 0 (0.0)
BSA, Body surface area; N/A, not applicable; PASI, Psoriasis Area and Severity Index.
*P values are from analysis of variance (ANOVA); PASI #10 vs 10\PASI #20 vs PASI[20. For continuous variables, differences by PASI group
were compared using ANOVA if normality was confirmed. Normality was assessed using skewness and Kurtosis z-scores, wherein a z-score of
\5.0 was considered as providing sufficient evidence for normality to use the parametric test.43 Researchers have found ANOVA to be
robust upward of a skewness z of 10 or 1244; however, we opted for a more conservative value of 5.0.
yP values are from Fisher exact test; PASI #10 vs 10\PASI #20 vs PASI[20. For categorical variables, differences by PASI group were
compared using Fisher exact test if expected counts were\5 patients per cell.
zP values are from Kruskal-Wallis test; PASI #10 vs 10\PASI #20 vs PASI[20. For continuous variables, differences by PASI group were
compared using Kruskal-Wallis if data were not normally distributed. Normality was assessed using skewness and Kurtosis z-scores, wherein
a z-score of\5.0 was considered as providing sufficient evidence for normality to use the parametric test.43 Researchers have found ANOVA
to be robust upward of a skewness z of 10 or 1244; however, we opted for a more conservative value of 5.0.
xP values are from x2; PASI #10 vs 10\PASI #20 vs PASI[20. For categorical variables, differences by PASI group were compared using the
x2 test if expected counts were $5 patients per cell.
{Among patients with at least 1 comorbid condition.
kHigher values indicate worse outcomes.
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Table II. Medication and health care resource use for moderate to severe plaque psoriasis patients in the past
6 months
Characteristic
Overall
(n = 200)
PASI #10
(n = 143, 71.5%)
10\PASI #20
(n = 36, 18.0%)
PASI[20
(n = 21, 10.5%) P value
No. of prescribed MSPP medications per patient
Mean (SD)* 1.5 (1.32) 1.5 (1.34) 1.3 (1.28) 2.1 (1.18) .0162
Median 1.0 1.0 1.0 2.0
No. of prescribed MSPP medications, n (%)y .0573
0 41 (20.5) 30 (21.0) 10 (27.8) 1 (4.8)
1 78 (39.0) 59 (41.3) 14 (38.9) 5 (23.8)
2 48 (24.0) 32 (22.4) 6 (16.7) 10 (47.6)
3 17 (8.5) 10 (7.0) 5 (13.9) 2 (9.5)
4 6 (3.0) 4 (2.8) 0 (0.0) 2 (9.5)
5 8 (4.0) 7 (4.9) 0 (0.0) 1 (4.8)
$6 2 (1.0) 1 (0.7) 1 (2.8) 0 (0.0)
No. of different physician-administered medications per
patient
Mean (SD)* 0.3 (0.47) 0.3 (0.46) 0.3 (0.53) 0.1 (0.36) .3078
Median 0.0 0.0 0.0 0.0
No. of physician-administered medications, n (%)z .1814
0 143 (71.5) 100 (69.9) 25 (69.4) 18 (85.7)
1 56 (28.0) 43 (30.1) 10 (27.8) 3 (14.3)
$2 1 (0.5) 0 (0.0) 1 (2.8) 0 (0.0)
No. of nonprescription treatments used
Mean (SD)*x 12.3 (25.04) 11.5 (24.52) 16.8 (30.66) 10.3 (16.64) .4239
Median 0.0 0.0 0.0 0.0
No. of nonprescription treatments, n (%)yx .2357
0 127 (63.5) 95 (66.4) 20 (55.6) 12 (57.1)
1 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0)
2 4 (2.0) 1 (0.7) 2 (5.6) 1 (4.8)
3 2 (1.0) 1 (0.7) 0 (0.0) 1 (4.8)
4 1 (0.5) 0 (0.0) 0 (0.0) 1 (4.8)
$5 65 (32.5) 45 (31.5) 14 (38.9) 6 (28.6)
No. of physician office visits
Mean (SD)* 3.4 (5.26) 3.2 (5.26) 4.1 (6.38) 2.8 (2.55) .3860
Median 2.0 1.0 2.0 2.0
No. of tests or procedures
Mean (SD)* 1.4 (4.87) 1.4 (4.81) 1.9 (6.02) 0.6 (2.62) .4014
Median 0.0 0.0 0.0 0.0
Patients receiving test or procedure at least oncez
Excimer laser 1.0000
No 186 (93.0) 132 (92.3) 34 (94.4) 20 (95.2)
Yes 14 (7.0) 11 (7.7) 2 (5.6) 1 (4.8)
No. of hospital outpatient or emergency department
visits
Mean (SD)* 0.0 (0.00) 0.0 (0.00) 0.0 (0.00) 0.0 (0.00) N/A
Median 0.0 0.0 0.0 0.0
Hospitalization, n (%)z 1 (0.5) 0 (0.0) 1 (2.8) 0 (0.0) .2850
No. of hospitalizations
Mean (SD)*{ 1.0 (.) 1.0 (.) N/A
Median 1.0 1.0
MSPP, Moderate to severe plaque psoriasis; N/A, not applicable; PASI, Psoriasis Area and Severity Index.
*P values are from Kruskal-Wallis test; PASI #10 vs 10\PASI #20 vs PASI[20. For continuous variables, differences by PASI group were
compared using Kruskal-Wallis if data were not normally distributed. Normality was assessed using skewness and Kurtosis z-scores, wherein
a z-score of\5.0 was considered as providing sufficient evidence for normality to use the parametric test.43 Researchers have found analysis
of variance to be robust upward of a skewness z of 10 or 1244; however, we opted for a more conservative value of 5.0.
yP values are from x2; PASI #10 vs 10\PASI #20 vs PASI[20. For categorical variables, differences by PASI group were compared using the
x2 test if expected counts were $5 patients per cell.
zP values are from Fisher exact test; PASI #10 vs 10\PASI #20 vs PASI[20. For categorical variables, differences by PASI group were
compared using Fisher exact test if expected counts were\5 patients per cell.
xIn the past 4 wk.
{Among those with a hospital stay.
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Table III. Changes in employment status, roles, and activities to manage moderate to severe plaque psoriasis
among the sample
Characteristic
Overall
(n = 200)
PASI #10
(n = 143, 71.5%)
10\PASI #20
(n = 36, 18.0%)
PASI[20
(n = 21, 10.5%) P value
Impact of psoriasis on employment status, n (%)* .4350
Retired early 1 (0.5) 1 (0.7) 0 (0.0) 0 (0.0)
Unemployed 2 (1.0) 1 (0.7) 0 (0.0) 1 (4.8)
Disabled 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Reduced work schedule 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
None 184 (92.0) 134 (93.7) 32 (88.9) 18 (85.7)
Missing 13 (6.5) 7 (4.9) 4 (11.1) 2 (9.5)
Patient-reported changes in activities and roles as a result of MSPP, n (%)*
Not doing same activities at work as before
psoriasis
\.0001
Somewhat/strongly agree 27 (13.5) 21 (14.7) 2 (5.6) 4 (19.1)
Neither agree or disagree 16 (8.0) 10 (7.0) 2 (5.6) 4 (19.1)
Somewhat/strongly disagree 128 (64.0) 91 (63.6) 25 (69.5) 12 (57.1)
Missing 29 (14.5) 21 (14.7) 7 (19.4) 1 (4.8)
Had to change job, role, or position at work
because of psoriasis
.0265
Somewhat/strongly agree 10 (5.0) 8 (5.6) 1 (2.8) 1 (4.8)
Neither agree or disagree 9 (4.5) 5 (3.5) 2 (5.6) 2 (9.5)
Somewhat/strongly disagree 152 (76.0) 108 (75.5) 26 (72.1) 18 (85.7)
Missing 29 (14.5) 22 (15.4) 7 (19.4) 0 (0.0)
Outside of work, not doing the same activities as a
result of psoriasis
.0002
Somewhat/strongly agree 48 (24.0) 27 (18.9) 13 (36.2) 8 (38.1)
Neither agree or disagree 15 (7.5) 8 (5.6) 3 (8.3) 4 (19.0)
Somewhat/strongly disagree 116 (58.0) 93 (65.0) 14 (38.9) 9 (42.9)
Missing 21 (10.5) 15 (10.5) 6 (16.7) 0 (0.0)
Time spent on activities related to MSPP during past 4 wk, miny
Vacuuming
Mean (SD)z 95.6 (218.65) 46.7 (43.69) 199.8 (406.33) 121.7 (151.83) .0145
Median 40.0 30.0 60.0 60.0
Washing sheets/clothes
Mean (SD)z 149.5 (256.37) 124.5 (271.85) 188.4 (263.95) 184.2 (185.58) .0943
Median 60.0 60.0 90.0 90.0
Putting on topical
Mean (SD)z 153.9 (318.80) 73.0 (107.82) 305.5 (592.43) 277.1 (276.85) .0003
Median 60.0 30.0 60.0 120.0
Going to the doctor
Mean (SD)z 109.5 (94.03) 105.6 (102.85) 115.8 (64.73) 124.0 (74.12) .2455
Median 60.0 60.0 120.0 120.0
Getting laboratory work/medical care, mean (SD)x 55.0 (55.82) 54.0 (61.98) 59.3 (57.48) 53.3 (36.70) .9754
Getting phototherapy treatment, mean (SD)x 178.3 (208.65) 213.9 (248.52) 146.8 (134.50) 15.0 (.) .6445
Other activities, mean (SD)x 31.3 (20.97) 31.3 (20.97) N/A
P values for the categorical variables are calculated for the nonmissing categories.
MSPP, Moderate to severe plaque psoriasis; N/A, not applicable; PASI, Psoriasis Area and Severity Index.
*P values are from Fisher exact test; PASI #10 vs 10\PASI #20 vs PASI[20. For categorical variables, differences by PASI group were
compared using Fisher exact test if expected counts were\5 patients per cell.
yAmong those spending any time on the specified activity.
zP values are from Kruskal-Wallis test; PASI #10 vs 10\PASI #20 vs PASI[20. For continuous variables, differences by PASI group were
compared using Kruskal-Wallis if data were not normally distributed. Normality was assessed using skewness and Kurtosis z-scores, wherein
a z-score of\5.0 was considered as providing sufficient evidence for normality to use the parametric test.43 Researchers have found analysis
of variance (ANOVA) to be robust upward of a skewness z of 10 or 1244; however, we opted for a more conservative value of 5.0.
xP values are from ANOVA; PASI#10 vs 10\PASI#20 vs PASI[20. For continuous variables, differences by PASI group were compared using
ANOVA if normality was confirmed. Normality was assessed using skewness and Kurtosis z-scores, wherein a z-score of\5.0 was considered
as providing sufficient evidence for normality to use the parametric test.43 Researchers have found ANOVA to be robust upward of a
skewness z of 10 or 1244; however, we opted for a more conservative value of 5.0.
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